Lymphoid malignancy
1 paper1 finding
- Humans1
Associations
1POT1
upin humans1HR 8.28
1 study
POT1
upin humans1HR 8.28
POT1 raises the risk of lymphoid malignancy in humans (HR 8.28, 95% CI 5.29-13.0).
“UK Biobank participants with pathogenic POT1 variants had long TL and higher lymphoid malignancy rates (45% by the age of 80 years; hazard ratio, 8.28; 95% confidence interval, 5.29-13.0).”
HumansUK Biobank participants with pathogenic POT1 variants
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome
Blood21 Jan 2026
Trial sponsors
1 trialPhase 1/28 people
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
1 trialEarly phase 17 people
Case Comprehensive Cancer Center
1 trialEarly phase 16 people
Latest
2 in 12 monthsNature Communications
Blood-based epigenetic instability linked to human aging and disease
Cohort study of 8,886 peopleBiomarkers
Blood
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome
Cohort study of 51 peopleTelomerase and telomere maintenance
The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Non-randomised trial in 55 peopleSenolytics